Martha Sola-Visner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Martha Sola-Visner has a total of 240 co-authors. Here are the top co-authors by number of shared publications:
Patricia Davenport
Division of Newborn Medicine, Boston Children's Hospital, Boston, MA; Harvard Medical School
9 shared publicationsZhi-Jian Liu
Division of Newborn Medicine, Boston Children's Hospital, Boston, Massachusetts, USA
9 shared publications- Patricia Davenport
Division of Newborn Medicine, Boston Children’s Hospital and Harvard Medical School, Boston, USA
7 shared publications - Francisca Ferrer-Marín
Hematology Department, Hospital Morales Meseguer, Universidad Católica San Antonio de Murcia, Centro de Investigación Biomédica en Red de Enfermedades Raras, Murcia, Spain
5 shared publications - Henry A. Feldman
Harvard Medical School Boston Massachusetts USA
5 shared publications - Cassandra D. Josephson
Johns Hopkins All Children's Hospital St. Petersburg Florida USA
4 shared publications
Latest Publications
- 1 November 2026
- Published by Wiley in Transfusion
Trends and determinants of peripartum blood transfusions
Background: Blood transfusion is critical in mitigating blood loss during delivery, but the epidemiology of peripartum blood transfusion in the United States is not fully understood. The objective of this study was to estimate trends in peripartum blood transfusions, including severe hemorrhage, and identify transfusion risk factors. Study Design and Methods: A retrospective cohort was assembled from the Recipient Epidemiology and Donor Study IV Pediatric (REDS‐IV‐P) database, which includes a network of hospitals and blood centers across four U.S. regional hubs. This included in‐hospital deliveries ≥24 weeks gestation from 2019 to 2024, with the outcome being any peripartum (within ±7 days of delivery) blood product transfusion. Bayesian Model Averaging (BMA) was used to examine associations. Results: There were 158,322 deliveries, with transfusion occurring in 4246 (11% were severe hemorrhage). Overall incidence of transfusion increased from ~2% early in the study period to ~3% in later years ( p < 0.001). The odds of peripartum transfusion were higher for deliveries where patients had an underlying hemoglobinopathy (adjusted odds ratio [aOR] [95% confidence interval; CI] aOR = 3.35 [2.65, 4.24]), venous thromboembolism (aOR = 3.25 [2.47, 4.26]), received hemostatic factor (aOR = 10.30 [9.58, 11.06]), mechanical ventilation (aOR = 13.91 [8.76, 22.11]), or hysterectomy (aOR = 13.68 [9.86, 18.96]). Conclusion: Peripartum transfusions are increasing across the REDS‐IV‐P hubs and are associated with underlying medical‐obstetric risk factors such as bleeding disorders and hemoglobinopathies. Our findings support the importance of early prenatal healthcare and identification of conditions that may help prevent peripartum hemorrhage and associated transfusions.
- 1 November 2026
- Published by Wiley in Transfusion
Trends and determinants of peripartum blood transfusions
Background: Blood transfusion is critical in mitigating blood loss during delivery, but the epidemiology of peripartum blood transfusion in the United States is not fully understood. The objective of this study was to estimate trends in peripartum blood transfusions, including severe hemorrhage, and identify transfusion risk factors. Study Design and Methods: A retrospective cohort was assembled from the Recipient Epidemiology and Donor Study IV Pediatric (REDS‐IV‐P) database, which includes a network of hospitals and blood centers across four U.S. regional hubs. This included in‐hospital deliveries ≥24 weeks gestation from 2019 to 2024, with the outcome being any peripartum (within ±7 days of delivery) blood product transfusion. Bayesian Model Averaging (BMA) was used to examine associations. Results: There were 158,322 deliveries, with transfusion occurring in 4246 (11% were severe hemorrhage). Overall incidence of transfusion increased from ~2% early in the study period to ~3% in later years ( p < 0.001). The odds of peripartum transfusion were higher for deliveries where patients had an underlying hemoglobinopathy (adjusted odds ratio [aOR] [95% confidence interval; CI] aOR = 3.35 [2.65, 4.24]), venous thromboembolism (aOR = 3.25 [2.47, 4.26]), received hemostatic factor (aOR = 10.30 [9.58, 11.06]), mechanical ventilation (aOR = 13.91 [8.76, 22.11]), or hysterectomy (aOR = 13.68 [9.86, 18.96]). Conclusion: Peripartum transfusions are increasing across the REDS‐IV‐P hubs and are associated with underlying medical‐obstetric risk factors such as bleeding disorders and hemoglobinopathies. Our findings support the importance of early prenatal healthcare and identification of conditions that may help prevent peripartum hemorrhage and associated transfusions.
- 31 August 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1-5
Redefining neonatal thrombocytopenia: an evidence-based approach, improved by the refineR algorithm
- 31 August 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1-5
Redefining neonatal thrombocytopenia: an evidence-based approach, improved by the refineR algorithm
- 27 July 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1-8
Pre-transfusion platelet counts and bleeding in very low birth weight infants
- 27 July 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1-8
Pre-transfusion platelet counts and bleeding in very low birth weight infants
- 8 June 2026
- Published by Springer Nature in Journal of Perinatology
Cryoprecipitate utilization in the neonatal intensive care unit: a single-center review
Significant variability exists in the indications for and dosing of cryoprecipitate transfusions. We examined cryoprecipitate transfusions in neonates with a focus on indications, dosing, and the incidence of multi-donor exposure. In this retrospective study, cryoprecipitate transfusions administered in a single neonatal intensive care unit from January 2022 to December 2024 were reviewed. Patient characteristics, diagnoses, laboratory values, and transfusion details were collected. In total, 50 patients received 104 cryoprecipitate transfusions. The median pre-transfusion fibrinogen level was 100 mg/dL (range 15-586), the median dose was 5.9 mL/kg (range 2.1-16.2), and the median increase in fibrinogen was 115 mg/dL (range -5 to 513). Based on the volume administered, 30% of transfusions likely resulted in multi-donor exposure, with no significant difference in the post-transfusion fibrinogen level achieved. Significant variation in cryoprecipitate transfusion practices exist, even within a single center. Increasing the weight-based dose of transfusion increases multi-donor exposure without significant clinical benefit.
- 8 June 2026
- Published by Springer Nature in Journal of Perinatology
Cryoprecipitate utilization in the neonatal intensive care unit: a single-center review
Significant variability exists in the indications for and dosing of cryoprecipitate transfusions. We examined cryoprecipitate transfusions in neonates with a focus on indications, dosing, and the incidence of multi-donor exposure. In this retrospective study, cryoprecipitate transfusions administered in a single neonatal intensive care unit from January 2022 to December 2024 were reviewed. Patient characteristics, diagnoses, laboratory values, and transfusion details were collected. In total, 50 patients received 104 cryoprecipitate transfusions. The median pre-transfusion fibrinogen level was 100 mg/dL (range 15-586), the median dose was 5.9 mL/kg (range 2.1-16.2), and the median increase in fibrinogen was 115 mg/dL (range -5 to 513). Based on the volume administered, 30% of transfusions likely resulted in multi-donor exposure, with no significant difference in the post-transfusion fibrinogen level achieved. Significant variation in cryoprecipitate transfusion practices exist, even within a single center. Increasing the weight-based dose of transfusion increases multi-donor exposure without significant clinical benefit.
- Open Access
- 2 April 2026
- Published by Springer Nature in Research Square
Pre-Transfusion Platelet Counts and Bleeding in Very Low Birth Weight Infants
Objective : Platelet transfusion thresholds for very low birth weight (VLBW, 3 /µL, respectively; P=0.7). However, infants with severe IVH had higher platelet counts (68.9x10 3 /µL) compared to the entire cohort (53.5x10 3 /µL, P=0.01). Conclusion : Infants with or without bleeding diagnoses had similar pre-transfusion platelet counts; infants with severe IVH had higher pre-transfusion platelet counts.
- 2 April 2026
- Published by Springer Nature in Research Square
Open AccessPre-Transfusion Platelet Counts and Bleeding in Very Low Birth Weight Infants
Objective : Platelet transfusion thresholds for very low birth weight (VLBW, 3 /µL, respectively; P=0.7). However, infants with severe IVH had higher platelet counts (68.9x10 3 /µL) compared to the entire cohort (53.5x10 3 /µL, P=0.01). Conclusion : Infants with or without bleeding diagnoses had similar pre-transfusion platelet counts; infants with severe IVH had higher pre-transfusion platelet counts.
- Open Access
- 12 March 2026
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (2)
Cross-species comparison of platelet proteomes reveals developmentally regulated metabolic and inflammatory changes
- 12 March 2026
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (2)
Open AccessCross-species comparison of platelet proteomes reveals developmentally regulated metabolic and inflammatory changes
- 17 January 2026
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 61 (5) , 162933
Adherence to a restrictive platelet transfusion guideline in a neonatal surgical population
- 17 January 2026
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 61 (5) , 162933
Adherence to a restrictive platelet transfusion guideline in a neonatal surgical population
- 12 January 2026
- Published by Springer Nature in Journal of Perinatology
- Vol. 46 (5) , 840-842
Neonatal outcomes following maternal red cell transfusions prior to or at delivery
- 12 January 2026
- Published by Springer Nature in Journal of Perinatology
- Vol. 46 (5) , 840-842
Neonatal outcomes following maternal red cell transfusions prior to or at delivery
- 25 February 2025
- Published by Elsevier in Seminars in Fetal and Neonatal Medicine
- Vol. 30 (1) , 101609
Recent advances in NICU platelet transfusions
- 25 February 2025
- Published by Elsevier in Seminars in Fetal and Neonatal Medicine
- Vol. 30 (1) , 101609
Recent advances in NICU platelet transfusions